Capricor Therapeutics, Inc. (CAPR) - Stock Analysis
Last updated: Jun 7, 2026
Research Idea
Research content for general circulation. Not individualized advice.Ā Methodology & Disclosures
High-risk regulatory/event play: FDA has resumed review of Capricor's BLA for Deramiocel after a Class 2 resubmission (PDUFA 2026-08-22), and management has flagged an imminent HOPEā3 top-line readout. The stock rallied ~24% over 21 days on this setup; with clear dated catalysts and recent institutional interest, trading into/around the HOPEā3 data window offers asymmetric near-term upside (balanced by binary trial and financing risk).
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ā¢ Strong Liquidity ā¢ No Revenue ā¢ Persistent Burn CAPR has a very strong balance sheet and ample liquidity, but its lack of revenue, persistent losses, and negative cash flow make operations the key risk.
Price Behavior
Key Price Behavior Insights: ā¢ Lower Highs ā¢ Fragile Support ā¢ Oversold Near Low Support Level: $26.90-$27.00 Resistance Level: $29.90-$30.00 Over the last month, CAPR has remained in a clear downtrend with lower highs and a fresh low near $26.71, leaving $26.90-$27.00 as fragile support and $29.90-$30.00 as the first meaningful rebound target.
Sentiment & News
Key News Insights: ā¢ Phase 3 success ā¢ August PDUFA ā¢ Launch litigation Capricor is advancing deramiocel toward an Aug. 22 FDA decision with strong Phase 3 data and a self-commercialization push, but ongoing distribution-related litigation with NS Pharma/Nippon Shinyaku adds launch uncertainty.
AI Summary
CAPR is now best viewed as a funded, near-term binary FDA/commercial launch catalyst rather than a cash-starved biotech, with enough runway to reach the August 22, 2026 deramiocel decision, but investors should stay cautious until approval, litigation clarity, and actual launch execution are proven.
Description
Capricor Therapeutics is a clinical-stage biotechnology company developing cell- and exosome-based therapies for a range of diseases. Its lead candidate, CAP-1002, has completed a Phase III trial in late-stage Duchenne muscular dystrophy and is in Phase II testing for SARSāCoVā2ārelated cytokine storm; the pipeline also includes a preclinical program for trauma-related injuries and vaccine candidates targeting COVIDā19. The company outsources clinical manufacturing of CAP-1002 to Lonza Houston, was founded in 2005, and is based in San Diego, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 10 | Mar 17 | CAPR | Capricor Therapeutics, Inc. | High-risk regulatory/event play: FDA has resumed review of Capricor's BLA for Deramiocel after a Class 2 resubmission (PDUFA 2026-08-22), and management has flagged an imminent HOPEā3 top-line readout. The stock rallied ~24% over 21 days on this setup; with clear dated catalysts and recent institutional interest, trading into/around the HOPEā3 data window offers asymmetric near-term upside (balanced by binary trial and financing risk). | Closed | -6.6% |